首页 | 本学科首页   官方微博 | 高级检索  
     

CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响
引用本文:金 科1,赵 丹1,杨 林2,朱剑梅1. CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响[J]. 现代肿瘤医学, 2019, 0(5): 723-727. DOI: 10.3969/j.issn.1672-4992.2019.05.003
作者姓名:金 科1  赵 丹1  杨 林2  朱剑梅1
作者单位:1.四川省医学科学院·四川省人民医院城东病区肿瘤科;2.创伤外科,四川 成都 610000
基金项目:四川省卫生和计划生育委员会科研课题(编号:140082)
摘    要:目的:分析CDK4/6抑制剂联合内分泌药物对人乳腺癌细胞中相关miRNA表达水平的影响。方法:培养人乳腺癌细胞MDA-MB-231、SK-BR-3、MCF-7株,使用CDK4/6抑制剂帕布昔利布和内分泌药物阿那曲唑作用于人乳腺癌细胞,MTT法检测细胞增殖情况,BD流式细胞仪检测细胞凋亡和细胞周期情况,采用RT-PCR检测相关miRNA表达情况,Western blot 检测TNF-α、Survivin蛋白表达。结果:在药物作用12 h、24 h、48 h和72 h后的MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞中miRNA-1321、miRNA-574-5p、miRNA-24-3p的表达水平均较对照组有所下降,而miRNA-1246、miRNA-494-3p、miRNA-29b-3p的表达水平有所升高;MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞G0/G1期、S期的比例均较对照组细胞均有所升高,而G2/M期比例与对照组相比较均有所下降;MDA-MB-231研究组、SK-BR-3研究组、MCF-7研究组细胞中TNF-α及Survivin的表达水平均较对照组有所上升。结论:CDK4/6抑制剂联合内分泌药物可以调节人乳腺癌细胞中相关miRNA表达水平,从而抑制人乳腺癌细胞增殖。

关 键 词:乳腺癌  CDK4/6抑制剂  内分泌治疗  微RNA  增殖

Effect of CDK4/6 inhibitor combined with endocrine therapy on miRNA expression in breast cancer cells
Jin Ke1,Zhao Dan1,Yang Lin2,Zhu Jianmei1. Effect of CDK4/6 inhibitor combined with endocrine therapy on miRNA expression in breast cancer cells[J]. Journal of Modern Oncology, 2019, 0(5): 723-727. DOI: 10.3969/j.issn.1672-4992.2019.05.003
Authors:Jin Ke1  Zhao Dan1  Yang Lin2  Zhu Jianmei1
Affiliation:1.Oncology Department;2.Traumatology Department,East Department of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,Sichuan Chengdu 610000,China.
Abstract:Objective:To analyze the effect of CDK4/6 inhibitor combined with endocrine drugs on the related miRNA expression in human breast cancer cells.Methods:The human breast cancer cell lines MDA-MB-231,SK-BR-3 and MCF-7 were cultured and treated with palbociclib and anastrozole.MTT was used to detect cell proliferation.BD flow cytometry was used to detect apoptosis and cell cycle.RT-PCR was used to detect the expression of miRNA.Western blot was used to detect the expression of TNF-α and Survivin protein.Results:The expression levels of miRNA-1321,miRNA-574-5p,miRNA-24-3p in the MDA-MB-231 group,SK-BR-3 group and MCF-7 group at 12 h,24 h,48 h and 72 h after drug treatment were lower than control group.But the expression levels of miRNA-1246,miRNA-494-3p and miRNA-29b-3p were significantly higher than those in the control group.The proportions of cells in G0/G1 phase and S phase in MDA-MB-231 group,SK-BR-3 group and MCF-7 group were higher than that in control group,while the ratio of G2/M phase was decreased compared with that in control group.In MDA-MB-231,SK-BR-3 and MCF-7 group,the levels of TNF-α and Survivin were all higher than those in the control group.Conclusion:CDK4/6 inhibitor combined with endocrine drugs can regulate the expression of related miRNAs in human breast cancer cells,thereby inhibiting the proliferation of human breast cancer cells.
Keywords:breast cancer   CDK4/6 inhibitor   endocrine therapy   microRNA   proliferation
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号